BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 18/08/2023

FDA Clears Path for Bortezomib Solution Concentrations

The FDA has determined that the 2.5mg/mL and 3.5mg/1.4mL concentrations of bortezomib solution were not withdrawn from sale due to safety or effectiveness concerns, allowing for potential approval of ANDAs for these formulations.

Source: Federal Register — Food and Drug AdministrationOpen original release →